# Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.

> **NCT07047651** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Dr. Stavroula Rakitzi** · enrollment: 84 (actual)

## Conditions studied

- Treatment Resistant Schizophrenia
- Treatment Resistant Bipolar Disorder

## Interventions

- **COMBINATION_PRODUCT:** Group A: (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol,anxiolytics: clonazepam, stedon, tavor antidepressants: seropram),
- **COMBINATION_PRODUCT:** Group B (Pharmacotherapy and TAU) (Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, antidepressants,
- **COMBINATION_PRODUCT:** Group C (Pharmacotherapy and Psychotherapy) Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, lithium, depakine
- **COMBINATION_PRODUCT:** Group D (Pharmacotherapy and TAU)Clozapine, quietiapine, olanzapine, aripiprazole, zyprasidone, risperidone, asenapine, paliperidone, clopixol, clonazepam, stedon, tavor, seropram, lithium, depakine)

## Key facts

- **NCT ID:** NCT07047651
- **Lead sponsor:** Dr. Stavroula Rakitzi
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-06-04
- **Primary completion:** 2027-12-20
- **Final completion:** 2027-12-20
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07047651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07047651, "Τhe Combination of Pharmacotherapy With RECOVERYTRSGR and RECOVERYTRSBDGR.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07047651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*